AUY922
- Generic Name
- AUY922
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H33N3O5
- CAS Number
- 747412-64-2
- Unique Ingredient Identifier
- G1G66XE93W
- Background
AUY922 has been used in trials studying the treatment of Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms, among others.
- Associated Conditions
- -
- Associated Therapies
- -
AUY922 in Patient With Stage IV NSCLC
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT01922583
- Locations
- π¨π³
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
π¨π³National Cheng Kung University Hospital, Tainan, Taiwan
π¨π³Taipei Veterans General Hospital, Taipei, Taiwan
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT01854034
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT01772797
- Locations
- πΊπΈ
Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
πΊπΈFox Chase Cancer Center Fox Chase Cancer (2), Philadelphia, Pennsylvania, United States
πͺπΈNovartis Investigative Site, Barcelona, Catalunya, Spain
AUY922 for Advanced ALK-positive NSCLC
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT01752400
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈBeth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01668173
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT01646125
- Locations
- πΊπΈ
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr., Los Angeles, California, United States
π¬π§Novartis Investigative Site, Leicester, United Kingdom
πΊπΈMaryland Oncology Hematology, P.A. SC, Rockville, Maryland, United States
PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT01613950
- Locations
- πΊπΈ
Massachusetts General Hospital Mass General 2, Boston, Massachusetts, United States
πΊπΈUniversity of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston, Texas, United States
π¨π³Novartis Investigative Site, Taipei, Taiwan
A Study of the HSP90 Inhibitor AUY922
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01485536
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 15
- Registration Number
- NCT01484860
- Locations
- π¨π¦
Princess Margaret Hospital, Toronto, Ontario, Canada
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT01404650
- Locations
- πΊπΈ
Florida Cancer Specialists-South, Ft. Myers, Florida, United States
πΊπΈYale School of Medicine, New Haven, Connecticut, United States
πΊπΈFlorida Hospital Cancer Institute, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.